14TH ALA Conference: MLS® and lymphoedema: the focus of a seminar

09 June 2022 - Trade fairs & Congresses -

MLS® Laser Therapy and its devices are among the protagonists of the “14th ALA Conference” (Hobart – Tasmania) thanks to the participation of the local distributor Heal With Laser, a long-term partner of the Australian Lymphology Association, sponsor of the Conference and organiser of a pre-meeting speed on the topic “Using laser therapy to treat and manage lymphoedema: proof and practice”. 

The seminar, by Dr. Kate Perkins, owner of “Cancer Rehabilitation and Lymphatic Solutions” and a long-time user of the M6 device, presented an MLS® treatment method combined with other methods and some clinical cases solved using ASA-branded therapy.

“Already in the past, Dr. Sharon Tilley, Physiotherapist at the “Lymphoedema and Laser Therapy clinic” in Adelaide, has pointed out how MLS® could be a valuable support in the treatment of lymphoedema. Dr. Perkins’ speech - explains Giacomo Granozio, ASA Area Manager – further confirms its value, also emphasised by an articulate case history presented during the meeting”.

 

Catherine Norton, CEO and founder of Heal With Laser, adds:

“During the workshop, prominence was also given to the research carried out by the team from Hasselt University, consisting of Jolien Robijns, Joy Lodewijckx and Jeroen Mebis: we consider their research to be a guiding light in this sector. While photobiomodulation is widely recognised for the effective treatment of wounds, for the reduction of musculoskeletal pain and for the accelerations of healing processes, the innovative use of MLS® for the treatment of issues related to COVID-19 was also discussed during the seminar, as proven by Dr. Scott Sigman's clinical study. His work was truly pioneering and has allowed many European specialists to replicate his insight: laser therapy is now successfully used to treat post-COVID patients”.

You might also be interested in ...

See all articles

Supportive Care in Cancer - Springer
blog - 04/04/2022
The clinical trial investigated the efficacy and safety of photobiomodulation therapy (PBMT) delivered by laser source (M6) in the prevention of chemotherapy-induced peripheral neuropathy (CIPN) in...
Effect of NIR Laser Therapy by MLS‐MiS Source on Fibroblast Activation by Inflammatory Cytokines in Relation to Wound Healing
blog - 12/04/2021
The ASA device have an important anti-inflammatory effect, but it is also effective in controlling fibroblast activation induced by IL‐1β and TNF‐α, probably responsible for a detrimental effect on...
M8 laser treatment for pain due to COVID-19
blog - 09/04/2021
The results actually showed that patients undergoing MLS® Laser Therapy had a rapid recovery
ASA Partners Meeting 2024
News - 21/03/2024
Four days of full immersion in the world of ASA to focus on the new devices - M-Hi and HIRO – and to analyse the biological effects of Hilterapia®.
ASAlaser @ FIF Milano 2024
News - 19/03/2024
Not only top-of-the-line devices, including the new HIRO and M-Hi as well as Magneto Qs and M8, but also three workshops aimed at highlighting the strengths of its therapies.
ASA tema @ ArabHealth 2024
News - 15/02/2024
In order to provide maximum visibility and the best dissemination of the strengths of its Therapeutic Solutions, the company preceded its attendance at the fair (Dubai, 29th January – 1st February)...